ADCX CANCER TREATMENT FRAMEWORK
LIVE

Serial Number

79451815

Owner

Adcytherix SAS

Filing Date

Mar 10, 2026

Add to watchlist:

No watchlists yet
View on USPTO

ADCX CANCER TREATMENT FRAMEWORK Trademark

Serial Number: 79451815

ADCX CANCER TREATMENT FRAMEWORK is a trademark filed by Adcytherix SAS on March 10, 2026. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Adcytherix SAS (4 trademarks)

4 Rue Léon Paulet

Entity Type: 98

Trademark Details

Filing Date

March 10, 2026

Registration Date

Not Registered

Goods & Services

Scientific research for medical purposes in the area of cancerous diseases; pharmaceutical products development; scientific and technological services and research in the field of chemistry, biotechnology, biopharmacy and medicine; preparation of biotechnological and biopharmaceutical analyses; development of new diagnostic methods; services in the field of developing new medicines, as included in this class; development of medical and veterinary preparations and medicines; biological research; chemical services; chemical laboratory services; conducting chemical analyses; conducting scientific research; research in the field of bacteriology; research in the field of chemistry; research and development services relating to new products for third parties; scientific research; medical research in the field of rare diseases; research and development in the pharmaceutical and biotechnology fields.

Drugs for medical purposes; anti-cancer drugs; anti-cancer preparations; compounds for treating cancer; biopharmaceuticals for the treatment of cancer; pharmaceuticals; pharmaceutical drugs; pharmaceutical products for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; sanitary preparations for medical purposes; dietetic preparations for medical purposes; adjuvants for medical purposes; antiseptics; medicinal products for human medical purposes; bacteriological preparations for medical purposes; bacteriological preparations for pharmaceutical use; biological preparations for medical purposes; chemicals for pharmaceutical use; chemical preparations for medical purposes; chemical preparations for veterinary purposes; chemical reagents for medical or veterinary purposes; diagnostic preparations for medical purposes; diagnostic agents for pharmaceutical use; dietary substances for medical purposes; protein preparations for medical purposes; elixirs (pharmaceutical preparations); feed additives for medical purposes; in vitro diagnostic preparations for medical purposes; capsules for medical purposes; germicidal detergents; dietary supplements for medical purposes; pharmaceutical preparations; preparations for sterilization.

Apparatus for the treatment of cancer; medical apparatus and instruments for administering pharmaceuticals; surgical, medical, dental and veterinary instruments and apparatus; surgical sutures; electromedical diagnostic instruments; analysers for medical purposes; apparatus for physical rehabilitation for medical purposes; diagnostic devices for medical purposes; medical instruments for therapeutic drug.

Filing History

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 23, 2026 RFCR
NON-FINAL ACTION WRITTEN
Jun 22, 2026 CNRT
ASSIGNED TO EXAMINER
Jun 18, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
Jun 12, 2026 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 12, 2026 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 11, 2026 REPR